PharVision Advisers’s Genesco GCO Stock Holding History

PharVision Advisers’s Portfolio GCO Stock Details GCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,713	Closed	-$340K	–	806
2025 Q3	$340K	Buy	+11,713	New	+$322K	0.19%	155

Other funds holding GCO

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

F1I

Fund 1 Investments Rincon, Puerto Rico $872M AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's GCO Position: Q4 2025 in Review

PharVision Advisers sold out of Genesco (GCO) in Q4 2025, closing a stake of 11,713 shares — an estimated $340K sold.

PharVision Advisers first reported a position in GCO in Q3 2025 and held it in 1 quarter. The position peaked at $340K in Q3 2025. 117 funds tracked by Wall St. Rank hold GCO as of Q4 2025.

PharVision Advisers reported no remaining Genesco position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 11,713 Genesco shares in Q4 2025, an estimated $340K.
PharVision Advisers first reported a position in Genesco in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Genesco position peaked at $340K in Q3 2025.
117 funds tracked by Wall St. Rank held Genesco as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.